REVLIMID Trials Exceed Pre-Specified Value
Celgene announced that analyses of both Phase III Special Protocol Assessment (SPA) multiple myeloma trials exceeded the pre-specified value for…
network
Celgene announced that analyses of both Phase III Special Protocol Assessment (SPA) multiple myeloma trials exceeded the pre-specified value for…